GoodRx Holdings, Inc. Class A Common Stock
GDRXGoodRx Holdings, Inc. Class A (GDRX) is a healthcare technology company that provides consumers with free access to prescription drug price comparisons and discounts. Founded in 2011, it aims to make healthcare more affordable by helping users find lower-cost medication options through its digital platform, including websites and mobile apps. GoodRx collaborates with pharmacies and healthcare providers to offer savings and streamline the medication purchasing process.
Company News
GoodRx faces revenue stagnation with Q1 2026 sales declining 4.4% year-over-year to $194 million, though its Pharma Direct business showed encouraging 82% growth. Meanwhile, Hims & Hers Health demonstrates strong momentum with 59% year-over-year revenue growth in Q4 2025 and 13% subscriber growth, capitalizing on rising healthcare costs and limit...
GoodRx Holdings shares rose 2.69% as the company expanded access to Novo Nordisk's Wegovy HD, a higher-dose GLP-1 treatment for self-pay patients priced at $399 per month. The expansion reflects growing demand for GLP-1 obesity treatments and GoodRx's efforts to simplify medication access. The company also recently expanded access to Eli Lilly's ...
Amazon has entered the GLP-1 weight loss drug market by offering Novo Nordisk's Wegovy pill through its pharmacy service at competitive prices ($25-$149 per month). This move could significantly impact competitors like Hims & Hers, WW International, and GoodRx, as Amazon leverages its 200 million Prime members and e-commerce platform. While the p...
Novo Nordisk launched its Wegovy weight loss pill in US pharmacies in December 2025 with competitive pricing starting at $149/month for self-pay patients. The pill demonstrated 17% average weight loss versus 3% for placebo. It's available through major retailers including CVS and Costco, as well as telehealth providers. Despite the positive produ...
Novo Nordisk announced a price reduction for Wegovy and Ozempic, offering a $199/month introductory rate for new self-pay patients, and lowering the standard monthly price from $499 to $349 to improve medication accessibility.
